|
Study characteristics
|
All studies n=94
|
Study source
|
|---|
|
AIFA websitea n=66
|
ClinicalTrials.govb n=28
|
|---|
|
Primary purpose, n (%)
| | | |
|
Treatment
|
86 (91%)
|
60 (91%)
|
26(93%)
|
|
Prevention
|
8 (9%)
|
6 (9%)
|
2 (7%)
|
|
Phase, n (%)
| | | |
|
1
|
3 (4%)
|
3 (5%)
|
-
|
|
1/2
|
1 (1%)
|
1 (2%)
| |
|
2
|
29 (34%)
|
20 (31%)
|
9 (43%)
|
|
2/3
|
19 (22%)
|
13 (20%)
|
6 (29%)
|
|
3
|
32 (38%)
|
26 (40%)
|
6 (29%)
|
|
4
|
1 (1%)
|
1 (2%)
|
-
|
|
Not reported
|
1
|
1
|
-
|
|
Not applicable
|
8
|
1
|
7
|
|
Sample sizec, n (%)
| | | |
|
1-100
|
26 (30%)
|
14 (23%)
|
12 (46%)
|
|
101-1000
|
53 (60%)
|
39 (63%)
|
14 (54%)
|
|
>1000
|
9 (10%)
|
9 (14%)
|
-
|
|
Not reported
|
6
|
4
|
2
|
|
Study design
| | | |
|
Single group
|
20 (22%)
|
9 (14%)
|
11 (39%)
|
|
Parallel group
|
69 (74%)
|
55 (85%)
|
14 (50%)
|
|
Cross over
|
1 (1%)
|
-
|
1 (4%)
|
|
Sequential
|
3 (3%)
|
1 (1%)
|
2 (7%)
|
|
Not reported
|
1
|
1
|
-
|
|
Randomization, n (%)
| | | |
|
Yes
|
70 (76%)
|
55 (85%)
|
15 (56%)
|
|
No
|
22 (24%)
|
10 (15%)
|
12 (44%)
|
|
Not reported
|
2
|
1
|
1
|
|
Masking, n (%)
| | | |
|
Yes
|
31 (33%)
|
25 (38%)
|
6 (21%)
|
|
No
|
62 (67%)
|
40 (62%)
|
22 (79%)
|
|
Not reported
|
1
|
1
|
-
|
|
Multicenter study, n (%)
| | | |
|
Yes
|
74 (80%)
|
56 (88%)
|
18 (64%)
|
|
No
|
18 (20%)
|
8 (12%)
|
10 (36%)
|
|
Not reported
|
2
|
2
|
-
|
|
International study, n (%)
| | | |
|
Yes
|
37 (40%)
|
31 (48%)
|
6 (21%)
|
|
No
|
55 (60%)
|
33 (52%)
|
22 (79%)
|
|
Not reported
|
2
|
2
|
-
|
|
Study sponsor, n (%)
| | | |
|
Industry
|
32 (34%)
|
27 (41%)
|
5 (18%)
|
|
No industry
|
62 (66%)
|
39 (59%)
|
23 (82%)
|
- Characteristics of COVID-19 interventional clinical trials planned to be carried out in Italy, overall and by data source (update: 6 April 2021)
- aAIFA website [14]
- bClinicalTrials.gov [16]
- cSample size, median (Interquartile range): overall, 243 (355), Study source: AIFA website, 285 (334); Study source: ClinicalTrials.gov, 149 (273)
